• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

August 17, 2015

Multigene Testing Recommended for Those Predisposed to Cancer

Author(s):

Davy James, Managing Editor

Many people who test negative for BRCA1 and BRCA2 harbor other harmful genetic mutations.

Many people who test negative for BRCA1 and BRCA2 harbor other harmful genetic mutations.

A new approach to testing for genetic mutations may be needed for many patients genetically predisposed, a recent study indicates.

Published in JAMA Oncology, the study noted that multigene testing of women who don’t carry the BRCA1 and BRCA2 mutations found that some may carry other harmful genetic mutations. Among these mutations are common to moderate-risk breast and ovarian cancer genes and Lynch syndrome genes, which increase the risk of ovarian cancer.

Multigene panel genetic testing are increasingly used in patients evaluated for a predisposition to hereditary breast and ovarian cancer. With utilization of these tests on the rise, researchers are concerned as many of the genes tested are low- to moderate-risk genes. Consensus management guidelines for these genes have yet to be introduced or were introduced recently, according to the study.

For the current study, researchers sought to evaluate how frequently multigene panel testing can identify mutations in need of clinical action among women who lack BRCA1 and BRCA2 mutations.

The study included 1046 women who underwent multigene panel testing. Among these women, 3.8% were negative for BRCA1 and BRCA2, but had harmful mutations in other moderate-risk genes.

An additional 23 women were included in the clinical management analysis of the study, which found that of 63 women testing positive for mutations, 33 women would be considered for disease-specific additional screening and additional preventative measures.

"Multigene panel testing for patients with suspected HBOC risk identifies substantially more individuals with relevant cancer risk gene mutations than does BRCA1/2 testing alone,” the researchers wrote. “Identifying such mutations is likely to change management for the majority of these individuals and their families in the near term, and in the long term should lead to development of effective management guidelines and improved outcomes for at-risk individuals.”

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
Image credit: Dr_Microbe | stock.adobe.com
Related Content
Advertisement
Scan of breast cancer -- Image credit: Science RF | stock.adobe.com
June 5th 2025

ASCO 2025: Camizestrant With CDK4/6 Inhibitor Improves PFS in Patients With HR+/HER2- Advanced Breast Cancer

Gillian McGovern, Associate Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Injectors and dosing pens for subcutaneous injection of antidiabetic medications or a anti-obesity medication lying on a pink backdrop, top view. Medicine and weight loss, concept.
June 4th 2025

Recombinant Human Hyaluronidase-Facilitated SCIg Sustains Clinical Remission in Idiopathic Inflammatory Myositis

Luke Halpern, Assistant Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Molecular biologist holding blood sample for EGFR mutation test for the diagnosis of lung disease. Epidermal Growth Factor Receptor.
June 4th 2025

Neoadjuvant Osimertinib With or Without Chemotherapy Improves Response in Resectable EGFRm NSCLC

Luke Halpern, Assistant Editor
Metabolic dysfunction-associated steatohepatitis (MASH) -- Image credit: Angelov | stock.adobe.com
June 4th 2025

GLP-1 Receptor Agonists and FGF21 Analogs May Be Key Treatments for MASH-Related Cirrhosis

Gillian McGovern, Associate Editor
Related Content
Advertisement
Scan of breast cancer -- Image credit: Science RF | stock.adobe.com
June 5th 2025

ASCO 2025: Camizestrant With CDK4/6 Inhibitor Improves PFS in Patients With HR+/HER2- Advanced Breast Cancer

Gillian McGovern, Associate Editor
S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk
June 3rd 2025

S2. Ep 56: Insights From a Pharmacy Times Peer Exchange: How to Talk the Talk

Alexandra Gerlach, Associate Editor
Injectors and dosing pens for subcutaneous injection of antidiabetic medications or a anti-obesity medication lying on a pink backdrop, top view. Medicine and weight loss, concept.
June 4th 2025

Recombinant Human Hyaluronidase-Facilitated SCIg Sustains Clinical Remission in Idiopathic Inflammatory Myositis

Luke Halpern, Assistant Editor
Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings
May 28th 2025

Insights from a Pharmacy Times Peer Exchange: Toxicity Monitoring and Management in Real-World Settings

Alexandra Gerlach, Associate Editor
Molecular biologist holding blood sample for EGFR mutation test for the diagnosis of lung disease. Epidermal Growth Factor Receptor.
June 4th 2025

Neoadjuvant Osimertinib With or Without Chemotherapy Improves Response in Resectable EGFRm NSCLC

Luke Halpern, Assistant Editor
Metabolic dysfunction-associated steatohepatitis (MASH) -- Image credit: Angelov | stock.adobe.com
June 4th 2025

GLP-1 Receptor Agonists and FGF21 Analogs May Be Key Treatments for MASH-Related Cirrhosis

Gillian McGovern, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.